3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Conditions
Breast Neoplasms
19
Neutropenia
13
Hodgkin Disease
5
Lymphoma
4
Lymphoma, Large B-Cell, Diffuse
3
Chemotherapy-induced Neutropenia
3
Triple Negative Breast Neoplasms
2
Febrile Neutropenia
2
Dendritic Cell Sarcoma, Interdigitating
2
Carcinoma, Non-Small-Cell Lung
2
Breast Neoplasms, Male
2
Sarcoma, Synovial
1
Sarcoma
1
Rhabdomyosarcoma
1
Recurrent Uterine Corpus Carcinoma
1
Rectal Neoplasms
1
Neurofibrosarcoma
1
Neoplasms, Germ Cell and Embryonal
1
Neoplasms
1
Neoplasm Metastasis
1
Multiple Myeloma
1
Lung Neoplasms
1
Liposarcoma
1
Leiomyosarcoma
1
Histiocytoma, Malignant Fibrous
1
Hemangiosarcoma
1
Heart Failure
1
Fibrosarcoma
1
Fever
1
Endometrial Adenocarcinoma
1
Interventions
Cisplatin
4
Etoposide
3
Carboplatin
3
etoposide phosphate
2
Paclitaxel
2
Bleomycin
2
pralsetinib
1
pembrolizumab
1
pegfilgrastim
1
Standard of Care
1
Specimen Handling
1
Respiratory Physiological Phenomena
1
Practice Guidelines as Topic
1
Platinum
1
Pemetrexed
1
Magnetic Resonance Spectroscopy
1
Injections
1
Ifosfamide
1
Granulocyte Colony-Stimulating Factor
1
Gemcitabine
1
Filgrastim
1
Biopsy
1
Aprepitant
1
130-nm albumin-bound paclitaxel
1
1,2-diaminocyclohexaneplatinum II citrate
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Neoplasms, Germ Cell and Embryonal
×
pegfilgrastim
×
Clear all
NCT02582697
2025-06-15
P3BEP
University of Sydney
Phase 3
Recruiting
500 enrolled